{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-101395","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2024-08-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.175530+00:00","generated_at":"2026-05-31T07:11:55.563675+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Director David Lucchino resigns; Katharine Knobil appointed to board","bullets":["David Lucchino resigned from board effective Aug 26, 2024; no disagreement with management or board.","Lucchino signed consulting agreement: $9k/quarter through 2026 annual meeting, then $2k/quarter through 2027; option grant (~$150k, capped 8k shares) at 2025 meeting, vesting at 2026 meeting.","Board reduced size from 7 to 6, then increased to 7 to appoint Katharine Knobil, M.D. as Class III director; also appointed to Compensation Committee.","Dr. Knobil will serve until 2025 annual meeting; receives standard non-employee director compensation and indemnification."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-101395","json":"https://secwatch.observer/filing/0000950170-24-101395.json","markdown":"https://secwatch.observer/filing/0000950170-24-101395.md","text":"https://secwatch.observer/filing/0000950170-24-101395.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024101395/0000950170-24-101395-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024101395/krro-20240826.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:11:55.563675+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2dfb6bec47","claim":"David L. Lucchino resigned as Director at Korro Bio, Inc..","evidence_excerpt":"On August 26, 2024, David L. Lucchino, a member of our Board of Directors, or the Board, notified us that he resigned from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024101395/0000950170-24-101395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"34389d9814","claim":"Katharine Knobil, M.D. was appointed as Director at Korro Bio, Inc..","evidence_excerpt":"and then increased the number of directors from six to seven to create a vacancy in Class III and then appointed Katharine Knobil, M.D. to fill the newly created vacancy on the Board in Class III effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000095017024101395/0000950170-24-101395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}